Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics)
用于指导序贯靶向抑制剂的时空肿瘤分析:免疫治疗组合(ST-Analytics)
基本信息
- 批准号:10708901
- 负责人:
- 金额:$ 254.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-22 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAdoptive Cell TransfersAlgorithmsAutomobile DrivingBiologicalBiopsyCalibrationCell physiologyCellsClinicalClinical DataClinical TrialsClinical Trials DesignCombination immunotherapyCombined Modality TherapyCommunitiesCoupledDataDatabasesDevelopmentDimensionsDisadvantagedDisease modelDistalDoseEducation and OutreachEducational ModelsEnvironmentEnvironment DesignEpigenetic ProcessEvaluationGenetic TranscriptionImmuneImmune systemImmunologic FactorsImmunooncologyImmunotherapyIndividualInternshipsK-12 EducationKineticsKnowledgeLeadLeadershipMalignant NeoplasmsMeasurementMetastatic malignant neoplasm to brainMitogen-Activated Protein Kinase InhibitorModelingNatureNeoplasm MetastasisOutcomePatientsPharmaceutical PreparationsPilot ProjectsPlayPrimary NeoplasmProteomicsResearchResearch PersonnelResearch Project GrantsResistanceResourcesRoleScienceScience, Technology, Engineering and Mathematics EducationScientistSelf-ExaminationSeriesStructureSystemSystems BiologyTherapeuticTimeTissuesVisualWorkbiobankcancer immunotherapycombinatorialcomputing resourcesdemographicsdesignimmune checkpoint blockadein silicoin vivoinhibitorinhibitor therapymedical schoolsmelanomamodel designmouse modelmultiple omicsoutreachoutreach programpreventprogramsrecruitspatiotemporaltooltranscriptomicstumortumor-immune system interactions
项目摘要
Overall Project Summary
The proposed U54 program Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor --
Immunotherapy Combinations (ST-Analytics) is designed to develop the recent conceptual advance that
targeted inhibitor + cancer immunotherapy (IT) combination treatments may yield significantly greater patient
benefit if those treatments are administered in sequence rather than simultaneously. Analysis of retrospective
clinical data coupled with in vivo therapeutic modeling using syngeneic models of murine melanoma strongly
support this concept. In fact, the picture that has emerged in melanoma is that immune factors can play a strong
role in driving resistance to MAPK inhibitor (MAPKi) therapy, and that lead-in immune checkpoint blockade (ICB)
can ‘prime’ both the primary tumor and distal metastases (including brain metastases) for eradication when the
IT is subsequently combined with MAPKi. This observation opens the doors for immune based strategies, such
as ICB or adoptive cell therapy (ACT), as sequential combinatorial agents to prevent MAPKi resistance.
However, this concept introduces a number of new variables, including dosing, sequence, and timing. This can
make the design and execution of clinical trials that can yield statistically significant outcomes impractical. This
is the scientific and translational problem we address in the proposed ST-Analytics U54.
The ST-Analytics U54 center is populated by leading scientists at the ISB, the UCLA Geffen School of Medicine,
and Yale, and is comprised of two research projects and two research cores, with each project integrating both
state-of-the-art experimentation and computational work. This structure is further designed to bring together the
scientific, experimental, and computational and administrative resources to develop a data base that captures
the kinetics of lead-in monotherapy tumor priming, and apply that data base to the development of predictive in
silico models that can inform the design of such targeted inhibitor – immunotherapy sequence combinations for
clinical trials. This requires close integration and cycles of iteration between of state-of-the-art experimentation,
leading edge computation, and realistic disease models, continuously calibrated through the analysis of highly
relevant, biopsied patient tumors. The resulting science also provides exciting opportunities for high impact
STEM outreach. We propose to act on those opportunities by leveraging a long-standing systems education
outreach program at ISB that already has impacted K-12 STEM education in all 50 states, and places an
emphasis on those communities that have been historically under-represented in STEM.
整体项目总结
建议的U54程序时空肿瘤分析用于指导序贯靶向抑制物--
免疫疗法组合(ST-Analytics)旨在发展最近的概念进展,即
靶向抑制物+癌症免疫疗法(IT)的联合治疗可能会产生更多的患者
如果这些治疗是按顺序进行的,而不是同时进行的,那么就会受益。回溯性分析
临床数据与同种小鼠黑色素瘤模型体内治疗模型的结合
支持这一概念。事实上,在黑色素瘤中出现的情况是免疫因素可以起到很强的作用
在MAPK抑制剂(MAPKi)治疗中的作用,以及引入免疫检查点阻断(ICB)
可以为根除原发肿瘤和远端转移瘤(包括脑转移瘤)做好准备
随后将其与MAPKi相结合。这一观察结果为基于免疫的策略打开了大门,例如
如ICB或过继细胞疗法(ACT),作为预防MAPKi耐药的序贯组合药物。
然而,这个概念引入了许多新的变量,包括剂量、顺序和时间。这可以
使设计和执行可以产生统计意义重大结果的临床试验变得不切实际。这
是我们在建议的ST-Analytics U54中解决的科学和翻译问题。
ST-Analytics U54中心由加州大学洛杉矶分校格芬医学院的顶尖科学家组成,
和耶鲁大学,由两个研究项目和两个研究核心组成,每个项目将两者整合在一起
最先进的实验和计算工作。此结构进一步设计为将
科学、实验、计算和管理资源,以开发捕获
引入单一疗法肿瘤启动动力学,并将该数据库应用于预测的发展。
可以为设计这样的靶向抑制剂-免疫治疗序列组合提供信息的计算机模型
临床试验。这需要在最先进的实验、
前沿计算和现实的疾病模型,通过高度的分析不断校准
相关的,活组织检查的患者肿瘤。由此产生的科学也为高影响力提供了令人兴奋的机会
向外伸展。我们建议通过利用长期的系统教育来抓住这些机会
ISB的外展计划已经影响了所有50个州的K-12 STEM教育,并将
将重点放在那些历史上在STEM中代表性不足的社区。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James R. Heath其他文献
Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
- DOI:
10.1186/s13073-023-01278-0 - 发表时间:
2024-01-06 - 期刊:
- 影响因子:11.200
- 作者:
Daniela Matuozzo;Estelle Talouarn;Astrid Marchal;Peng Zhang;Jeremy Manry;Yoann Seeleuthner;Yu Zhang;Alexandre Bolze;Matthieu Chaldebas;Baptiste Milisavljevic;Adrian Gervais;Paul Bastard;Takaki Asano;Lucy Bizien;Federica Barzaghi;Hassan Abolhassani;Ahmad Abou Tayoun;Alessandro Aiuti;Ilad Alavi Darazam;Luis M. Allende;Rebeca Alonso-Arias;Andrés Augusto Arias;Gokhan Aytekin;Peter Bergman;Simone Bondesan;Yenan T. Bryceson;Ingrid G. Bustos;Oscar Cabrera-Marante;Sheila Carcel;Paola Carrera;Giorgio Casari;Khalil Chaïbi;Roger Colobran;Antonio Condino-Neto;Laura E. Covill;Ottavia M. Delmonte;Loubna El Zein;Carlos Flores;Peter K. Gregersen;Marta Gut;Filomeen Haerynck;Rabih Halwani;Selda Hancerli;Lennart Hammarström;Nevin Hatipoğlu;Adem Karbuz;Sevgi Keles;Christèle Kyheng;Rafael Leon-Lopez;Jose Luis Franco;Davood Mansouri;Javier Martinez-Picado;Ozge Metin Akcan;Isabelle Migeotte;Pierre-Emmanuel Morange;Guillaume Morelle;Andrea Martin-Nalda;Giuseppe Novelli;Antonio Novelli;Tayfun Ozcelik;Figen Palabiyik;Qiang Pan-Hammarström;Rebeca Pérez de Diego;Laura Planas-Serra;Daniel E. Pleguezuelo;Carolina Prando;Aurora Pujol;Luis Felipe Reyes;Jacques G. Rivière;Carlos Rodriguez-Gallego;Julian Rojas;Patrizia Rovere-Querini;Agatha Schlüter;Mohammad Shahrooei;Ali Sobh;Pere Soler-Palacin;Yacine Tandjaoui-Lambiotte;Imran Tipu;Cristina Tresoldi;Jesus Troya;Diederik van de Beek;Mayana Zatz;Pawel Zawadzki;Saleh Zaid Al-Muhsen;Mohammed Faraj Alosaimi;Fahad M. Alsohime;Hagit Baris-Feldman;Manish J. Butte;Stefan N. Constantinescu;Megan A. Cooper;Clifton L. Dalgard;Jacques Fellay;James R. Heath;Yu-Lung Lau;Richard P. Lifton;Tom Maniatis;Trine H. Mogensen;Horst von Bernuth;Alban Lermine;Michel Vidaud;Anne Boland;Jean-François Deleuze;Robert Nussbaum;Amanda Kahn-Kirby;France Mentre;Sarah Tubiana;Guy Gorochov;Florence Tubach;Pierre Hausfater;Isabelle Meyts;Shen-Ying Zhang;Anne Puel;Luigi D. Notarangelo;Stephanie Boisson-Dupuis;Helen C. Su;Bertrand Boisson;Emmanuelle Jouanguy;Jean-Laurent Casanova;Qian Zhang;Laurent Abel;Aurélie Cobat - 通讯作者:
Aurélie Cobat
C60's smallest cousin
C60 的最小“亲戚”
- DOI:
10.1038/31579 - 发表时间:
1998-06-25 - 期刊:
- 影响因子:48.500
- 作者:
James R. Heath - 通讯作者:
James R. Heath
Protein Catalyzed Capture (PCC) Agents for Antigen Targeting.
用于抗原靶向的蛋白质催化捕获 (PCC) 试剂。
- DOI:
- 发表时间:
2022 - 期刊:
- 影响因子:0
- 作者:
M. Idso;B. Lai;Heather D Agnew;James R. Heath - 通讯作者:
James R. Heath
Planar Patch-Clamp Electrodes for Single Cell and Neural Network Studies
- DOI:
10.1016/j.bpj.2009.12.3287 - 发表时间:
2010-01-01 - 期刊:
- 影响因子:
- 作者:
John M. Nagarah;Daniel A. Wagenaar;James R. Heath - 通讯作者:
James R. Heath
Stereochemical engineering of a peptide macrocycle allosteric inhibitor of phospho-Akt2 controls cell penetration by fine-tuning macrocycle-cell membrane interactions
磷酸 Akt2 肽大环变构抑制剂的立体化学工程通过微调大环 - 细胞膜相互作用来控制细胞渗透
- DOI:
10.26434/chemrxiv-2021-kldh7 - 发表时间:
2021 - 期刊:
- 影响因子:5.9
- 作者:
Arundhati Nag;A. Mafi;Samir R Das;Mary Beth Yu;Belen Alvarez;W. Goddard;James R. Heath - 通讯作者:
James R. Heath
James R. Heath的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James R. Heath', 18)}}的其他基金
PROJECT 1: TIME-Based Spatiotemporal Cancer Immunograms Predictive for Immunotherapy-Targeted Therapy Sequential Combinations
项目 1:基于时间的时空癌症免疫图预测免疫治疗靶向治疗顺序组合
- 批准号:
10907268 - 财政年份:2022
- 资助金额:
$ 254.9万 - 项目类别:
Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics)
用于指导序贯靶向抑制剂的时空肿瘤分析:免疫治疗组合(ST-Analytics)
- 批准号:
10526101 - 财政年份:2022
- 资助金额:
$ 254.9万 - 项目类别:
PROJECT 1: TIME-Based Spatiotemporal Cancer Immunograms Predictive for Immunotherapy-Targeted Therapy Sequential Combinations
项目 1:基于时间的时空癌症免疫图预测免疫治疗靶向治疗顺序组合
- 批准号:
10526103 - 财政年份:2022
- 资助金额:
$ 254.9万 - 项目类别:
PROJECT 1: TIME-Based Spatiotemporal Cancer Immunograms Predictive for Immunotherapy-Targeted Therapy Sequential Combinations
项目 1:基于时间的时空癌症免疫图预测免疫治疗靶向治疗顺序组合
- 批准号:
10708924 - 财政年份:2022
- 资助金额:
$ 254.9万 - 项目类别:
Data-driven Patient-Specific Agent Based Models of Metastatic Melanoma for Immunotherapy Response Prediction
用于免疫治疗反应预测的数据驱动的基于患者特异性药物的转移性黑色素瘤模型
- 批准号:
10831325 - 财政年份:2022
- 资助金额:
$ 254.9万 - 项目类别:
Nano and biomolecular engineered technologies for neoantigen-specific T cell capture and characterization
用于新抗原特异性 T 细胞捕获和表征的纳米和生物分子工程技术
- 批准号:
10297588 - 财政年份:2021
- 资助金额:
$ 254.9万 - 项目类别:
Nano and biomolecular engineered technologies for neoantigen-specific T cell capture and characterization
用于新抗原特异性 T 细胞捕获和表征的纳米和生物分子工程技术
- 批准号:
10489832 - 财政年份:2021
- 资助金额:
$ 254.9万 - 项目类别:
Nano and biomolecular engineered technologies for neoantigen-specific T cell capture and characterization
用于新抗原特异性 T 细胞捕获和表征的纳米和生物分子工程技术
- 批准号:
10673935 - 财政年份:2021
- 资助金额:
$ 254.9万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 254.9万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 254.9万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 254.9万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 254.9万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 254.9万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 254.9万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 254.9万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 254.9万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 254.9万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 254.9万 - 项目类别:
Research Grant